Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials

Heidi Taipale; Johannes Schneider‐Thoma; Justo Pinzón-Espinosa; Joaquim Raduà; Orestis Efthimiou; Christiaan H. Vinkers; Ellenor Mittendorfer‐Rutz; Narcı́s Cardoner; Luís Pintor; Antti Tanskanen; Anneka Tomlinson; Paolo Fusar‐Poli; Andrea Cipriani; Eduard Vieta; Stefan Leucht; Jari Tiihonen; Jurjen J. Luykx

doi:10.1001/jamapsychiatry.2021.3990

Abstract

1 min read

RCTs may represent only about a fifth of real-world individuals with schizophrenia spectrum disorders. Underrepresented (ineligible) patients with schizophrenia spectrum disorders have moderately higher risks of admission due to psychosis while receiving maintenance treatment than RCT-eligible patients. These findings set the stage for future studies targeting real-world populations currently not represented by RCTs.

Related publications

Article2019

A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real‐world populations in psoriasis

Zenas Z N Yiu, K.J. Mason, Juliet N. Barker, Philip Hampton, Kathleen McElhone, Catherine Smith, Richard B. Warren, Christopher Em Griffiths, Mark Lunt, A. David Burden

Article2025

#3436 Representation of women and sex-disaggregated outcomes of trials in ANCA-associated vasculitis

Vanja Ivković, Annette Bruchfeld, Lauren Floyd, Andreas Kronbichler, Jennifer S. Lees, Karl Emil Nelveg-Kristensen, Jae Il Shin, Maria Weiner, Kate Stevens

Article2019

Safety of direct oral anticoagulants in real–world clinical practice: translating the trials to everyday clinical management

Ameenathul M. Fawzy, Wangyang Yang, Professor Gregory Lip

Preprint2020

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials

Cathrine Axfors, Andreas M. Schmitt, Perrine Janiaud, Janneke van ’t Hooft, Sherief Abd‐Elsalam, Ehab Fawzy Abdo, Benjamin S. Abella, Javed Akram, Ravi K. Amaravadi, Derek Angus, Yaseen M. Arabi, Shehnoor Azhar, Lindsey R. Baden, Arthur W. Baker, Leïla Belkhir, Thomas Benfield, Marvin A. H. Berrevoets, Cheng‐Pin Chen, Tsung‐Chia Chen, Shu‐Hsing Cheng, Chien‐Yu Cheng, Wei‐Sheng Chung, Yehuda Z. Cohen,

Article2018

A real-world comparison of drug discontinuation rates between clinical trial eligible and ineligible patients in the British Association of Dermatologists Biologic Interventions Register (BADBIR).

K.J. Mason, Juliet N. Barker, Kay Hogan Smith, Philip Hampton, Mark Lunt, Kathleen McElhone, Richard Warren, Zenas Z N Yiu, Christopher Em Griffiths, A. David Burden